A six-year-old boy presented to hospital after accessing his father’s lithium tablets. It was unclear how many tablets were in the container and whether the child had taken any.
The lithium was stored in a plastic bottle with a child-resistant cap. On examining the cap, it was noted that the child-resistant mechanism would not engage unless downward pressure was applied while closing the cap. Without the downward pressure, the cap spun freely and would not engage to a fixed closure point. When this occurred, the cap could then be opened in the same manner as a simple screw cap. There were no instructions on the cap to say that downward pressure was required to activate the child-resistant mechanism. This procedure is not required for the majority of other child-resistant caps used on the Australian market. The child needed to be observed for six hours. No adverse events emerged so he was discharged.
Currently, there is no requirement for companies marketing medicines in Australia to perform post-production quality assurance testing of the functionality of child-resistant caps, although a few companies do perform these tests. Minor alterations to the bottle, cap or wadding can have significant impacts on the functionality of the child-resistant cap, and these defects can only be discovered at the end of the manufacturing chain. Ideally, they should be detected before the product is marketed.
The collation of reports of failures of child-resistant packaging is hampered by the lack of national standardisation of poisons information data in Australia and the inconsistency of product and packaging specific detail within those data. There are currently efforts underway to address this.
Patients should ensure that their medicines are kept out of reach of children, for example by storing the drugs in a locked container. However, this is only feasible when medication is not in use, and anecdotally, some exposures occur in the brief interval when the medication is being accessed to take a dose, or when it is being packed for travel. Effective child-resistant packaging is an important secondary prevention strategy in these scenarios. Consumer awareness of medication toxicity and poisoning prevention in young children could also be improved at the point of prescription and dispensing.
Conflict of interest: none declared
Comment by the Therapeutic Goods Administration
The TGA and the sponsor company investigated this case and found no evidence that the packaging of the relevant batch was defective when released for sale. As such, the reported issue of the child-resistant mechanism failing to engage unless downward pressure was applied while closing was found to be an isolated defect, the cause of which is unknown and may have occurred after purchase.
Child-resistant closures for medicines marketed in Australia are manufactured and tested to very high standards. However, like any mass-produced good, there may be the occasional defective unit.
All suspected child-resistant packaging defects should be reported to the TGA or sponsor so that they can be investigated.
Scheduled medicines are required to carry the warning ‘KEEP OUT OF REACH OF CHILDREN’ in bold text, placed prominently at the top of the label. The container of the lithium carbonate tablets referred to in the report carried this warning.
It is important to note that child-resistant closures are not childproof. If they were, it would be difficult or impossible for many elderly people and arthritis sufferers to open them.
Child-resistant closures are tested on four-year-old children. The child in the report was six years old.
The requirements for child-resistant packaging of medicines are set out in Therapeutic Goods Order No. 80 ‘Child-Resistant Packaging Requirements for Medicines’.
Health professionals who receive a report of a suspected child-resistant packaging defect from a patient should consider sending the packaging to the TGA or sponsor so that the defect can be verified and properly assessed.